InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
3
Disclosed sells
0
T+90 hit rate
75%
T+90 mean return
+5.9%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Broadfoot Jill Marie, Chief Financial Officer. Insider active across 4 companies, notably Acelrx Pharmaceuticals INC. Cumulatively, 12 disclosures have been logged. Split: 3 buys · 0 sell. Total volume traded: €31k. Activity tracked since 20 November 2021. The latest transaction was disclosed on 24 June 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations12 total
5,100 sharesCommon StockSEC:0001305178-26-000002:0
3,750 sharesCommon StockSEC:0000950170-25-013884:0
2,174 shares0Common StockSEC:0001415889-24-018073:0
5,000 shares@ US$1.7942.1% of flowCommon StockSEC:0000950170-24-067668:0
Ideal exit: 25 Feb 2025 (T+270)
3,750 sharesCommon stockSEC:0001209191-24-002947:0
581 shares0Common StockSEC:0001209191-23-058479:0
3,750 sharesCommon stockSEC:0001209191-23-007364:0
15,500 shares0Common StockSEC:0001209191-22-042311:0
1,923 shares@ US$6.750.015% mcap100.0% of flowCommon stockSEC:0001209191-22-003419:0
Ideal exit: 10 Oct 2022 (T+270)
1,923 shares@ US$6.75100.0% of flowCommon stockSEC:0001209191-22-003419
Ideal exit: 10 Oct 2022 (T+270)
15,000 shares0Common StockSEC:0001209191-21-066559:0
15,000 shares0Common StockSEC:0001209191-21-066559
12 of 12 declarations
About Broadfoot Jill Marie
Jill Marie Broadfoot is a Director and Chief Financial Officer at AcelRx Pharmaceuticals Inc and aTYR Pharma Inc. She oversees the financial operations of these companies, including budgeting and risk management. AcelRx Pharmaceuticals and aTYR Pharma are biopharmaceutical companies. Jill's expertise in finance is essential to ensure the financial health of these companies.
